Topigen Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Topigen Pharmaceuticals Inc. plans to mount a full-scale attack on chronic respiratory ailments such as asthma, COPD and allergic rhinitis, with mRNA-interfering drugs that target multiple pathways. Its lead compound, for asthma, combines two antisense molecules to target at least eight different components of the inflammatory response.